Zoetis Inc (NYSE:ZTS) EVP Roxanne Lagano sold 4,463 shares of the business’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $125.99, for a total transaction of $562,293.37. Following the completion of the transaction, the executive vice president now owns 33,190 shares of the company’s stock, valued at approximately $4,181,608.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of ZTS stock opened at $126.64 on Friday. The company has a current ratio of 4.17, a quick ratio of 2.87 and a debt-to-equity ratio of 2.74. The firm has a fifty day moving average price of $118.06 and a 200 day moving average price of $105.25. The company has a market cap of $60.93 billion, a P/E ratio of 40.46, a PEG ratio of 3.20 and a beta of 0.92. Zoetis Inc has a 12 month low of $78.90 and a 12 month high of $128.41.
Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $0.90 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.08. The firm had revenue of $1.55 billion during the quarter, compared to the consensus estimate of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.77 earnings per share. On average, equities analysts forecast that Zoetis Inc will post 3.57 EPS for the current year.
Several research firms have commented on ZTS. Barclays boosted their price target on shares of Zoetis from $120.00 to $135.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 7th. Zacks Investment Research downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Monday, May 6th. Craig Hallum boosted their price target on shares of Zoetis from $132.00 to $138.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Stifel Nicolaus boosted their price target on shares of Zoetis from $110.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, July 22nd. Finally, BMO Capital Markets boosted their price target on shares of Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a research note on Thursday, May 9th. Seven research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $115.13.
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Recommended Story: Understanding Options Trading
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.